{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:18:55Z","timestamp":1790054335438,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1136\/ard.2007.072967","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T00:34:01Z","timestamp":1184978041000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":359,"title":["Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"67","author":[{"given":"T","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Tatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kamatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Inokuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.072967_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1136\/ard.2007.072967_bib2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.072967_bib3","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.072967_bib7","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.072967_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial","volume":"49","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2007.072967_bib9","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). A randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.072967_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/s10165-004-0357-7","article-title":"Proposed Japanese guidelines for the use of infliximab for rheumatoid arthritis [Erratum: Mod Rheumatol 2005;15:322]","volume":"15","author":"Miyasaka","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard.2007.072967_bib12","first-page":"37","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis","volume":"33","author":"Abe","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072967_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1128\/JCM.38.4.1461-1467.2000","article-title":"Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups","volume":"38","author":"Sing","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1136\/ard.2007.072967_bib14","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072967_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/rheumatology\/keh071","article-title":"Detection of Pneumocystis carinni by DNA amplification in patients with connective tissue disease: re-evaluation of clinical features of P. carinni pneumonia in rheumatic diseases","volume":"43","author":"Saito","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.072967_bib19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724219075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724219075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.072967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:39:28Z","timestamp":1737250768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724219075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0003496724219075"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.072967","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.072967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}